STOCK TITAN

Cartesian Growth Financials

REEUF
Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Cartesian Growth (REEUF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak
1/9

Cartesian Growth passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality
0.51x

For every $1 of reported earnings, Cartesian Growth generates $0.51 in operating cash flow (-$774K OCF vs -$1.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
N/A
EBITDA
N/A
Net Income
-$1.5M
YoY-118.4%

Cartesian Growth reported -$1.5M in net income in fiscal year 2025. This represents a decrease of 118.4% from the prior year.

EPS (Diluted)
$-0.12

Cartesian Growth earned $-0.12 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
N/A
Cash & Debt
$237K
YoY+0.0%

Cartesian Growth held $237K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
9M

Cartesian Growth had 9M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
Return on Equity
N/A

Capital Allocation

R&D Spending
N/A
Share Buybacks
$51.2M
YoY-48.6%

Cartesian Growth spent $51.2M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 48.6% from the prior year.

Capital Expenditures
N/A

REEUF Income Statement

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A N/A N/A N/A
Gross Profit N/A N/A N/A N/A N/A N/A N/A N/A
R&D Expenses N/A N/A N/A N/A N/A N/A N/A N/A
SG&A Expenses N/A N/A N/A N/A N/A N/A N/A N/A
Operating Income -$203K+22.5% -$262K-34.2% -$195K N/A -$217K-9.4% -$198K+11.2% -$223K N/A
Interest Expense N/A N/A N/A N/A N/A N/A N/A N/A
Income Tax N/A N/A N/A N/A N/A N/A N/A N/A
Net Income $338K+322.1% -$152K-127.2% $560K N/A $2.9M+38.1% $2.1M-16.9% $2.5M N/A
EPS (Diluted) N/A N/A N/A N/A N/A N/A N/A N/A

REEUF Balance Sheet

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Total Assets $88.6M+1.4% $87.4M+1.6% $86.0M+1.1% $85.0M-53.5% $182.8M+1.6% $179.9M+1.5% $177.3M+1.6% $174.6M
Current Assets $115K-68.2% $360K+26.3% $285K-35.0% $439K+74.6% $251K+40.5% $179K-50.0% $357K+8.3% $330K
Cash & Equivalents $44K-80.8% $230K+182.6% $81K-65.7% $237K+18.5% $200K+424.8% $38K-68.5% $121K+137.0% $51K
Inventory N/A N/A N/A N/A N/A N/A N/A N/A
Accounts Receivable N/A N/A N/A N/A N/A N/A N/A N/A
Goodwill N/A N/A N/A N/A N/A N/A N/A N/A
Total Liabilities $112.0M+2.1% $109.7M+2.7% $106.8M+1.5% $105.3M-47.9% $202.0M+1.4% $199.3M+1.6% $196.1M+1.5% $193.1M
Current Liabilities $5.4M+15.0% $4.7M+18.6% $4.0M+14.1% $3.5M+18.2% $2.9M+20.0% $2.5M+23.7% $2.0M+29.4% $1.5M
Long-Term Debt N/A N/A N/A N/A N/A N/A N/A N/A
Total Equity -$23.4M-5.0% -$22.3M-7.2% -$20.8M-2.8% -$20.3M-5.2% -$19.3M+0.6% -$19.4M-3.5% -$18.7M-1.0% -$18.5M
Retained Earnings -$23.4M-5.0% -$22.3M-7.2% -$20.8M-2.8% -$20.3M-5.2% -$19.3M+0.6% -$19.4M-3.5% -$18.7M-1.0% -$18.5M

REEUF Cash Flow Statement

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Operating Cash Flow -$186K-82.6% -$102K+34.6% -$155K+66.4% -$463K-424.4% -$88K-6.8% -$83K+54.1% -$180K+62.1% -$476K
Capital Expenditures N/A N/A N/A N/A N/A N/A N/A N/A
Free Cash Flow N/A N/A N/A N/A N/A N/A N/A N/A
Investing Cash Flow -$750K-15.4% -$650K-44.4% -$450K-100.5% $99.2M+22136.4% -$450K0.0% -$450K0.0% -$450K N/A
Financing Cash Flow $750K-16.7% $900K+100.0% $450K+100.5% -$98.7M-14194.8% $700K+55.6% $450K-35.7% $700K+100.9% -$76.6M
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A N/A

REEUF Financial Ratios

Metric Q2'26 Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24
Gross Margin N/A N/A N/A N/A N/A N/A N/A N/A
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin N/A N/A N/A N/A N/A N/A N/A N/A
Return on Equity N/A N/A N/A N/A N/A N/A N/A N/A
Return on Assets 0.4%+0.5pp -0.2%-0.8pp 0.7% N/A 1.6%+0.4pp 1.2%-0.3pp 1.4% N/A
Current Ratio 0.02-0.1 0.080.0 0.07-0.1 0.13+0.0 0.09+0.0 0.07-0.1 0.18-0.0 0.22
Debt-to-Equity -4.78+0.1 -4.92+0.2 -5.13+0.1 -5.20+5.3 -10.49-0.2 -10.28+0.2 -10.47-0.1 -10.42
FCF Margin N/A N/A N/A N/A N/A N/A N/A N/A

Note: Shareholder equity is negative (-$26.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.06), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Frequently Asked Questions

No, Cartesian Growth (REEUF) reported a net income of -$1.5M in fiscal year 2025.

Cartesian Growth (REEUF) reported diluted earnings per share of $-0.12 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cartesian Growth (REEUF) generated -$774K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Cartesian Growth (REEUF) had $38.3M in total assets as of fiscal year 2025, including both current and long-term assets.

Yes, Cartesian Growth (REEUF) spent $51.2M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Cartesian Growth (REEUF) had 9M shares outstanding as of fiscal year 2025.

Cartesian Growth (REEUF) had a current ratio of 0.06 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Cartesian Growth (REEUF) had a debt-to-equity ratio of -2.45 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Cartesian Growth (REEUF) had a return on assets of -4.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Cartesian Growth (REEUF) had $237K in cash against an annual operating cash burn of $774K. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Cartesian Growth (REEUF) has negative shareholder equity of -$26.3M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Cartesian Growth (REEUF) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Cartesian Growth (REEUF) has an earnings quality ratio of 0.51x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top